For millions of adults worldwide, peanut allergy is more than a dietary inconvenience—it is a constant life-threatening hazard. From navigating food labels to avoiding certain restaurants and social gatherings, the burden is immense. However, recent findings from a groundbreaking clinical trial in the United Kingdom have opened new possibilities for adults living with this chronic fear.
In what researchers are calling a “life-changing” study, adults diagnosed with peanut allergies were able to safely build tolerance to the allergen through carefully monitored daily doses. This method, known as oral immunotherapy, has been widely applied to children with encouraging results. Yet, until now, evidence supporting its effectiveness in adults has been limited.
Led by Professor Stephen Till, Professor of Allergy at King’s College London, the “Grown Up Peanut Immunotherapy” (GU-PIT) trial marks the first controlled clinical effort to explore this treatment in adults. Published in the peer-reviewed journal Allergy, the Phase II trial offers renewed hope for adults previously told that lifelong avoidance was their only option.
“The only way to manage a peanut allergy has traditionally been strict avoidance,” Professor Till explained. “Constant fear of life-threatening reactions places a huge burden on people with peanut allergy.”
The trial involved 21 adults aged 18 to 40, each with a clinically confirmed peanut allergy. Researchers introduced them to minuscule doses of peanut flour—starting at just 0.8 milligrams, less than 1% of a whole peanut. The participants, who were carefully monitored in a clinical setting, gradually increased their daily intake over several weeks. Those who could tolerate the initial doses began a structured “build-up phase,” returning to the clinic every two weeks to receive incrementally larger amounts, ranging from 6 milligrams up to 1 gram—the equivalent of about four peanuts.
Once participants reached this daily intake of one gram, they maintained it for four weeks. Their tolerance was then tested through a rigorous double-blind, placebo-controlled food challenge. In this final evaluation, participants were given increasing doses of either peanut or a placebo under medical supervision to confirm their desensitization.
The results were remarkable: 67% of participants successfully consumed at least five peanuts without experiencing allergic reactions. Even more encouraging, participants were instructed to continue consuming peanuts daily at home to maintain their newfound tolerance.
“Many participants who completed the trial told us that the treatment had been life-changing and they were no longer living in fear,” said Allergy Dietitian Hannah Hunter from Guy’s and St Thomas’ NHS Foundation Trust, one of the study’s lead authors.
One such participant is Chris, who had lived with peanut allergy since infancy. After nearly three decades of avoiding even the slightest trace of peanuts, Chris describes the impact as transformative.
“I’m so happy to say that I used to be allergic to peanuts, but thanks to this trial, this is no longer a concern,” he shared. “All of my life I had associated the taste and smell of peanuts with fear and death. Now, I have four peanuts every day with my breakfast to maintain my immunity.”
Chris described how the daily fear of accidental exposure once controlled his life. “Previously, a tiny mistake could have life-threatening impacts, but now I don’t have the fear that I might collapse and die from eating a takeaway food.”
While these results offer newfound hope, Professor Till cautioned that this treatment is not a cure, but a management strategy. “We are very pleased with the results,” he said. “The efficacy rate is broadly in line with peanut oral immunotherapy trials in children.”
Hunter added that the trial’s impact extends beyond the physical. “Everyday situations such as eating in restaurants and attending social events are anxiety–provoking. The condition also affects travel choices and career options. We found that quality of life significantly improved after oral immunotherapy,” she noted.
Looking ahead, the research team aims to expand their work through larger-scale clinical trials to confirm the results and explore the possibility of achieving long-term tolerance. The hope is that with continued research, this approach could eventually become a standardized treatment available to adults worldwide.
For now, the GU-PIT trial stands as a beacon of hope—proving that with careful management and medical supervision, adults too can break free from the constraints of peanut allergy and reclaim their quality of life.
Recommended For You
